Study Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.
Want to learn more about this trial?
Request More InfoInterventions
IM19 CAR-TBIOLOGICAL
All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Beijing hospital | Beijing | China | |
| Peking University People's Hospital (PKUPH) | Beijing | China |